drugset / Trial / NCT01637142
A Study of LY2140023 in Healthy Participants
Non-randomizedCrossoverOpen-labelBasic science
Summary
The purpose of this study is to assess the extent and rate of absorption of LY2140023 in healthy participants. The study has two periods. In Treatment Period 1, participants will receive a single oral dose of 80 milligrams (mg) LY2140023 followed by a 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) \[14C\]-LY2140023. In Treatment Period 2, participants will receive an oral dose of 80 mg LY2140023 followed by a 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi \[14C\]-LY404039. There will be at least a 3-day washout between doses.
Timeline
- Start
- 2012-07
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2140023 | Unknown | 100 ug | Oral |
| Subject | LY2140023 | Unknown | 80 mg | Oral |
| Subject | LY404039 | Small molecule | 100 ug | Intravenous |
Indications
No indication recorded.